Cancers, Vol. 12, Pages 901: Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant

Cancers, Vol. 12, Pages 901: Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant:



Cancers, Vol. 12, Pages 901: Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant

Cancers doi: 10.3390/cancers12040901

Authors:
Camille Libre
Ludovic Moro-Sibilot
Stéphane Giraud
Laetitia Martin
Els Verhoeyen
Caroline Costa
Amel Chebel
Nathalie Bissay
Gilles Salles
Laurent Genestier
Pierre Sujobert


Targeted therapies have improved the outcome of cancer, but their efficacy is intrinsically limited by the emergence of subclones with a mutation in the gene encoding the target protein. A few examples of collateral sensitivity have demonstrated that the conformational changes induced by these mutations can create unexpected sensitivity to other kinase inhibitors, but whether this concept can be generalized is unknown. Here is described the development of a model to screen a library of kinase inhibitors for collateral sensitivity drugs active on the Bruton Tyrosine Kinase (BTK) protein with the ibrutinib resistance mutation C481S. First, we demonstrate that overexpression of the constitutively active mutant of BTK harboring the E41K mutation in Ba/F3 cells creates an oncogenic addiction to BTK. Then, we have exploited this phenotype to perform a screen of a kinase inhibitor library on cells with or without the ibrutinib resistance mutation. The BTK inhibitors showed the expected sensitivity profile, but none of the drugs tested had a specific activity against the C481S mutant of BTK, suggesting that extending the collateral sensitivity paradigm to all kinases targeted by cancer therapy might not be trivial.